États-Unis · Plateformes & données · Finviz

FocalTherics to Announce Third Quarter 2026 Financial Results on November 5, 2026

Publié par Finviz · États-Unis il y a 3 j

AUSTIN, Texas, Oct. 22, 2026 (GLOBE NEWSWIRE)-- FocalTherics (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced that it will release its…

Lire l'article complet sur Finviz Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finviz.com)

FocalTherics to Announce Third Quarter 2026 Financial Results on November 5, 2026

À lire aussi

Vanguard S&P 500 ETF Long-Term Outlook: What Historical Trends Suggest for Patient Investors

Oppenheimer reiterates Amgen stock rating on cancer drug data

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Stock Has Consensus Target Price of $492.90

Roche lung cancer drug extends survival by nearly six months in late-stage trial

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

Samsung’s Galaxy Fit 4 could undercut Fitbit by $120

FocalTherics to Announce Third Quarter 2026 Financial Results on November 5, 2026

Partager

À lire aussi

Vanguard S&P 500 ETF Long-Term Outlook: What Historical Trends Suggest for Patient Investors

Oppenheimer reiterates Amgen stock rating on cancer drug data

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Stock Has Consensus Target Price of $492.90

Roche lung cancer drug extends survival by nearly six months in late-stage trial

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

Samsung’s Galaxy Fit 4 could undercut Fitbit by $120